2 weeks Ago By ABMN Staff
Investment analysts at StockNews.com started coverage on shares of vTv Therapeutics ( NASDAQ:VTVT – Get Free Report ) in a research report issued to clients and investors on Wednesday. The brokerage set a “sell” rating on the biotechnology company’s stock.
Separately, HC Wainwright assumed coverage on vTv Therapeutics in a research report on Wednesday, April 9th. They set a “buy” rating and a $36.00 target price on the stock.
Check Out Our Latest Report on vTv Therapeutics vTv Therapeutics Price Performance vTv Therapeutics ( NASDAQ:VTVT – Get Free Report ) last released its earnings results on Thursday, March 20th. The biotechnology company reported ($0.55) EPS for the quarter, topping the consensus estimate of ($0.
87) by $0.32. The firm had revenue of $0.
02 million during the quarter. Hedge Funds Weigh In On vTv Therapeutics An institutional investor recently raised its position in vTv Therapeutics stock. Geode Capital Management LLC increased its position in vTv Therapeutics Inc.
( NASDAQ:VTVT – Free Report ) by 12.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 11,634 shares of the biotechnology company’s stock after buying an additional 1,327 shares during the quarter.
Geode Capital Management LLC owned about 0.36% of vTv Therapeutics worth $158,000 as of its most recent filing with the Securities and Exchange Commission. 17.
51% of the stock is currently owned by institutional investors and hedge funds. vTv Therapeutics Company Profile ( Get Free Report ) vTv Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes.
Recommended Stories Receive News & Ratings for vTv Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter ..
